Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of $15.31 billion and $2.14, respectively.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said. Merck said last week its biggest ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...